<DOC>
	<DOCNO>NCT00757757</DOCNO>
	<brief_summary>This study evaluate safety efficacy MCS110 patient prostate cancer bone metastasis</brief_summary>
	<brief_title>A Phase I/II Open-label Study MCS110 Patients With Prostate Cancer Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>Patients asymptomatic castrateresistant prostate cancer bone metastases receive bisphosphonates 12 month prior enrollment 18 year old Plan cytotoxic biologic therapy study Active dental problem Active heart complication Active infection Patients moderate severe swell due fluid Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>anti-M-CSF</keyword>
	<keyword>M-CSF antibody</keyword>
	<keyword>M-CSF</keyword>
	<keyword>Prostate Cancer bone metastasis</keyword>
</DOC>